{"id":10321,"date":"2025-12-02T23:34:31","date_gmt":"2025-12-02T20:34:31","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10321"},"modified":"2025-12-02T23:34:31","modified_gmt":"2025-12-02T20:34:31","slug":"entrectinib-nedir-trk-ros1-alk-inhibitoru-endikasyonlari-ve-beyin-metastazlarindaki-rolu","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10321","title":{"rendered":"Entrectinib Nedir? TRK\/ROS1\/ALK \u0130nhibit\u00f6r\u00fc, Endikasyonlar\u0131 ve Beyin Metastazlar\u0131ndaki Rol\u00fc"},"content":{"rendered":"<h2>Entrectinib Nedir? K\u00fc\u00e7\u00fck Molek\u00fcl Bir TRK\/ROS1\/ALK \u0130nhibit\u00f6r\u00fcne Yak\u0131ndan Bak\u0131\u015f<\/h2>\n<p><strong>Entrectinib<\/strong> (ticari ad\u0131yla Rozlytrek), kanser tedavisinde \u00f6ne \u00e7\u0131kan, a\u011f\u0131zdan al\u0131nan k\u00fc\u00e7\u00fck molek\u00fcl yap\u0131da bir tirozin kinaz inhibit\u00f6r\u00fcd\u00fcr. \u00d6zellikle <strong>NTRK1, NTRK2, NTRK3 (TRKA\/B\/C)<\/strong>, <strong>ROS1<\/strong> ve <strong>ALK<\/strong> f\u00fczyonlar\u0131n\u0131 hedef al\u0131r ve bu sayede \u201cak\u0131ll\u0131 mermi\u201d benzetmesini ger\u00e7e\u011fe d\u00f6n\u00fc\u015ft\u00fcr\u00fcr. T\u00fcm\u00f6r h\u00fccrelerinde ortaya \u00e7\u0131kan bu gen f\u00fczyonlar\u0131, h\u00fccre b\u00fcy\u00fcmesini durdurulamayan bir \u201ca\u00e7\u0131k gaz pedal\u0131\u201d gibi s\u00fcrekli aktif sinyal yollar\u0131na neden olur.<\/p>\n<p>Entrectinib, bu anormal kinazlar\u0131 bloke ederek t\u00fcm\u00f6r h\u00fccresinin b\u00fcy\u00fcmesini, \u00e7o\u011falmas\u0131n\u0131 ve hayatta kalmas\u0131n\u0131 engellemeye \u00e7al\u0131\u015f\u0131r. Klinik \u00f6ncesi ve erken faz \u00e7al\u0131\u015fmalarda, NTRK f\u00fczyonlu t\u00fcm\u00f6rlerde g\u00fc\u00e7l\u00fc antit\u00fcm\u00f6r aktivite g\u00f6stermesi, bu molek\u00fcl\u00fc k\u0131sa s\u00fcrede hedefe y\u00f6nelik tedavilerin parlayan y\u0131ld\u0131zlar\u0131ndan biri haline getirmi\u015ftir (doi:10.1158\/2159-8290.CD-17-0605; doi:10.1016\/j.ctrv.2020.102073).<\/p>\n<h2>T\u00fcm\u00f6r Agnostik Yakla\u015f\u0131m: Organ De\u011fil, Molek\u00fcler \u0130mza \u00d6nemli<\/h2>\n<p>Entrectinib\u2019i benzersiz k\u0131lan en \u00f6nemli \u00f6zelliklerden biri, <strong>t\u00fcm\u00f6r agnostik<\/strong> yakla\u015f\u0131m\u0131n somut bir \u00f6rne\u011fi olmas\u0131d\u0131r. Yani bu ila\u00e7, akci\u011fer, kolon, tiroid veya t\u00fckr\u00fck bezi fark etmeksizin; e\u011fer t\u00fcm\u00f6rde <strong>NTRK gen f\u00fczyonu<\/strong> varsa devreye girebilir.<\/p>\n<p>Bug\u00fcn entrectinib, a\u015fa\u011f\u0131daki solid t\u00fcm\u00f6rlerde, uygun molek\u00fcler hedef saptand\u0131\u011f\u0131nda se\u00e7enek olarak g\u00fcndeme gelmektedir:<\/p>\n<ul>\n<li>NTRK f\u00fczyonlu eri\u015fkin ve pediatrik solid t\u00fcm\u00f6rler<\/li>\n<li>ROS1 pozitif metastatik k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK)<\/li>\n<li>Nadir g\u00f6r\u00fclen, standart tedavi se\u00e7enekleri s\u0131n\u0131rl\u0131 t\u00fcm\u00f6r tipleri<\/li>\n<\/ul>\n<p>Bu yakla\u015f\u0131m, klasik \u201corgan bazl\u0131 onkoloji\u201d anlay\u0131\u015f\u0131ndan \u201c<strong>molek\u00fcler bazl\u0131 onkoloji<\/strong>\u201dye ge\u00e7i\u015fin en etkileyici \u00f6rneklerinden biridir (doi:10.1002\/cncr.32725; doi:10.1158\/1078-0432.CCR-19-1706).<\/p>\n<h2>Entrectinib ve Beyin Metastazlar\u0131: Kan-Beyin Bariyerini A\u015fan K\u00fc\u00e7\u00fck Molek\u00fcl<\/h2>\n<p>Bir\u00e7ok hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7, <strong>kan-beyin bariyerini<\/strong> yeterince ge\u00e7emedi\u011fi i\u00e7in beyin metastazlar\u0131nda s\u0131n\u0131rl\u0131 etki g\u00f6sterir. Entrectinib ise bu noktada \u00f6nemli bir avantaja sahiptir: Merkezi sinir sistemine (MSS) anlaml\u0131 penetrasyon sa\u011flayabildi\u011fi g\u00f6sterilmi\u015ftir.<\/p>\n<p>Klinik \u00e7al\u0131\u015fmalarda, beyin metastaz\u0131 bulunan <strong>ROS1 pozitif KHDAK<\/strong> hastalar\u0131nda ve NTRK f\u00fczyonlu t\u00fcm\u00f6rlerde MSS lezyonlar\u0131nda dikkat \u00e7ekici yan\u0131t oranlar\u0131 bildirilmi\u015ftir (doi:10.1200\/JCO.18.01215; doi:10.1016\/S1470-2045(19)30332-6). Bu \u00f6zellik, \u00f6zellikle beyne s\u0131k metastaz yapan akci\u011fer kanseri gibi t\u00fcm\u00f6rlerde, entrectinib\u2019i stratejik bir tedavi se\u00e7ene\u011fi haline getirir.<\/p>\n<h2>Yan Etkiler ve G\u00fcvenlik Profili: Nelere Dikkat Edilmeli?<\/h2>\n<p>Her hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl gibi entrectinib de belirli bir <strong>yan etki profiline<\/strong> sahiptir. Genel olarak tolere edilebilir kabul edilse de, d\u00fczenli takip gerektiren baz\u0131 \u00f6nemli toksisiteler s\u00f6z konusudur.<\/p>\n<p>En s\u0131k bildirilen yan etkiler \u015funlard\u0131r (doi:10.1016\/S1470-2045(19)30332-6):<\/p>\n<ul>\n<li>Yorgunluk, ba\u015f d\u00f6nmesi<\/li>\n<li>Tat alma bozukluklar\u0131 (disgeuzi)<\/li>\n<li>Kilo art\u0131\u015f\u0131 ve periferik \u00f6dem<\/li>\n<li>Bulant\u0131, ishal veya kab\u0131zl\u0131k gibi gastrointestinal \u015fik\u00e2yetler<\/li>\n<li>QT aral\u0131\u011f\u0131 uzamas\u0131, kalp fonksiyonunda de\u011fi\u015fiklikler<\/li>\n<\/ul>\n<p>Bu nedenle, entrectinib tedavisi ba\u015flanmadan \u00f6nce ve tedavi s\u0131ras\u0131nda <strong>EKG, kardiyak de\u011ferlendirme, karaci\u011fer ve b\u00f6brek fonksiyon testleri<\/strong> yak\u0131ndan izlenmelidir. \u00d6zellikle kardiyak risk fakt\u00f6r\u00fc olan hastalarda ila\u00e7 etkile\u015fimleri ve doz ayarlamalar\u0131 dikkatle planlanmal\u0131d\u0131r.<\/p>\n<h2>Ki\u015fiselle\u015ftirilmi\u015f Kanser Tedavisinde Entrectinib\u2019in Rol\u00fc<\/h2>\n<p>Entrectinib, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n <strong>ki\u015fiselle\u015ftirilmi\u015f t\u0131p<\/strong> vizyonunu nas\u0131l ger\u00e7e\u011fe d\u00f6n\u00fc\u015ft\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6steren g\u00fc\u00e7l\u00fc bir \u00f6rnektir. Tedavi s\u00fcreci kabaca \u015fu ad\u0131mlarla ilerler:<\/p>\n<ul>\n<li>\u00d6nce t\u00fcm\u00f6rden veya kandan <strong>molek\u00fcler genetik analiz<\/strong> (NGS, FISH, RT-PCR vb.) yap\u0131l\u0131r.<\/li>\n<li>E\u011fer NTRK, ROS1 veya ALK f\u00fczyonu saptan\u0131rsa, klasik kemoterapi yerine daha hedefe y\u00f6nelik bir tedavi g\u00fcndeme gelir.<\/li>\n<li>Hasta, organ bazl\u0131 de\u011fil, <strong>molek\u00fcler imza bazl\u0131<\/strong> bir tedaviye y\u00f6nlendirilir.<\/li>\n<\/ul>\n<p>Bu sayede hem tedavi etkinli\u011fi artabilir hem de gereksiz toksisite azalt\u0131labilir. G\u00fcncel \u00e7al\u0131\u015fmalar, entrectinib ve benzeri TRK inhibit\u00f6rlerinin gelecekte daha erken hastal\u0131k evrelerinde, kombine protokollerde ve adjuvan\/neo-adjuvan senaryolarda daha fazla kullan\u0131laca\u011f\u0131n\u0131 \u00f6ng\u00f6rmektedir (doi:10.1038\/s41571-019-0269-1).<\/p>\n<h2>Entrectinib Hakk\u0131nda S\u0131k Sorulan Sorular (SSS)<\/h2>\n<h3>1. Entrectinib hangi kanser t\u00fcrlerinde kullan\u0131l\u0131r?<\/h3>\n<p>Entrectinib, <strong>NTRK gen f\u00fczyonu<\/strong> ta\u015f\u0131yan eri\u015fkin ve pediatrik solid t\u00fcm\u00f6rlerde, ayr\u0131ca <strong>ROS1 pozitif metastatik k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde<\/strong> kullan\u0131l\u0131r. Burada belirleyici olan t\u00fcm\u00f6r\u00fcn k\u00f6ken ald\u0131\u011f\u0131 organ de\u011fil, NTRK veya ROS1 f\u00fczyonunun varl\u0131\u011f\u0131d\u0131r (doi:10.1002\/cncr.32725).<\/p>\n<h3>2. Entrectinib ile larotrectinib aras\u0131nda ne fark var?<\/h3>\n<p>Her iki ila\u00e7 da TRK inhibit\u00f6r\u00fcd\u00fcr; ancak <strong>entrectinib<\/strong> ayn\u0131 zamanda ROS1 ve ALK kinazlar\u0131n\u0131 da hedefler ve MSS penetrasyonu y\u00fcksektir. Hasta se\u00e7imi yap\u0131l\u0131rken t\u00fcm\u00f6r\u00fcn molek\u00fcler profili, e\u015flik eden hastal\u0131klar ve yan etki profili birlikte de\u011ferlendirilir (doi:10.1038\/s41571-019-0269-1).<\/p>\n<h3>3. Entrectinib tedavisi ne kadar s\u00fcrer?<\/h3>\n<p>Genellikle <strong>hastal\u0131k progresyonu<\/strong> geli\u015fene veya hasta <strong>tolere edilemeyen toksisite<\/strong> ya\u015fayana kadar devam eder. Tedavi s\u00fcresi, klinik yan\u0131t\u0131n s\u00fcresi, yan etkilerin \u015fiddeti ve hastan\u0131n genel performans durumuna g\u00f6re bireyselle\u015ftirilir (doi:10.1200\/JCO.18.01215).<\/p>\n<h3>4. Entrectinib \u00e7ocuklarda da kullan\u0131labilir mi?<\/h3>\n<p>Evet. NTRK f\u00fczyonlu pediatrik solid t\u00fcm\u00f6rlerde, belirli ya\u015f ve kilo s\u0131n\u0131rlar\u0131 \u00e7er\u00e7evesinde entrectinib kullan\u0131m\u0131na dair klinik veriler ve onay mevcuttur. \u00d6zellikle standart tedavilere diren\u00e7li veya cerrahi olarak \u00e7\u0131kar\u0131lamayan t\u00fcm\u00f6rlerde \u00f6nemli bir se\u00e7enek sunar (doi:10.1002\/cncr.32725).<\/p>\n<h3>5. Entrectinib ba\u015flamadan \u00f6nce hangi testler yap\u0131lmal\u0131d\u0131r?<\/h3>\n<p>\u00d6ncelikle t\u00fcm\u00f6r dokusunda veya sirk\u00fcle t\u00fcm\u00f6r DNA\u2019s\u0131nda <strong>NTRK, ROS1 veya ALK f\u00fczyonlar\u0131n\u0131<\/strong> g\u00f6steren molek\u00fcler testler (NGS panelleri, FISH, RT-PCR) yap\u0131lmal\u0131d\u0131r. Ayr\u0131ca tedavi \u00f6ncesinde <strong>EKG, kardiyak de\u011ferlendirme, karaci\u011fer ve b\u00f6brek fonksiyon testleri<\/strong> ile bazal durum belirlenmeli ve tedavi boyunca d\u00fczenli aral\u0131klarla takip edilmelidir (doi:10.1158\/1078-0432.CCR-19-1706).<\/p>\n<h2>Kaynaklar (DOI)<\/h2>\n<p>10.1158\/2159-8290.CD-17-0605<br \/>\n10.1016\/j.ctrv.2020.102073<br \/>\n10.1002\/cncr.32725<br \/>\n10.1158\/1078-0432.CCR-19-1706<br \/>\n10.1200\/JCO.18.01215<br \/>\n10.1016\/S1470-2045(19)30332-6<br \/>\n10.1038\/s41571-019-0269-1<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Entrectinib (Rozlytrek) nedir, nas\u0131l etki eder? NTRK, ROS1 ve ALK f\u00fczyonlu t\u00fcm\u00f6rlerde t\u00fcm\u00f6r agnostik yakla\u015f\u0131m, beyin metastazlar\u0131ndaki etkinli\u011fi ve hedefe y\u00f6nelik kanser tedavisindeki yeri hakk\u0131nda detayl\u0131 inceleme.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[870,872,866,814,873,868,861,869,867,871],"class_list":["post-10321","post","type-post","status-publish","format-standard","hentry","category-molekul","tag-alk-inhibitoru","tag-beyin-metastazi","tag-entrectinib","tag-hedefe-yonelik-tedavi","tag-kucuk-molekul-tirozin-kinaz-inhibitoru","tag-ntrk-fuzyonu","tag-onkoloji","tag-ros1-pozitif-akciger-kanseri","tag-rozlytrek","tag-tumor-agnostik-tedavi"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10321"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10321\/revisions"}],"predecessor-version":[{"id":10322,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10321\/revisions\/10322"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}